93 related articles for article (PubMed ID: 10774248)
1. [Effect of lenograstim (glycosylated recombinant human granulocyte-colony stimulating factor) on peripheral blood stem cell mobilization in healthy volunteers].
Ohnishi A; Uchino M; Asano S
Rinsho Ketsueki; 2000 Mar; 41(3):198-205. PubMed ID: 10774248
[TBL] [Abstract][Full Text] [Related]
2. A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Lenograstim/Breast Cancer Study Group.
Narabayashi M; Takeyama K; Fukutomi T; Tokuda Y; Tajima T; Okumura A; Chou T; Sano M; Makino H; Igarashi T; Sasaki Y; Imoto S; Ogura M; Morishima Y; Murai H; Okamoto S; Ikeda T; Kasai M; Yokozawa T; Tobinai K
Jpn J Clin Oncol; 1999 Jun; 29(6):285-90. PubMed ID: 10418556
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and adverse events following 5-day repeated administration of lenograstim, a recombinant human granulocyte colony-stimulating factor, in healthy subjects.
Akizuki S; Mizorogi F; Inoue T; Sudo K; Ohnishi A
Bone Marrow Transplant; 2000 Nov; 26(9):939-46. PubMed ID: 11100272
[TBL] [Abstract][Full Text] [Related]
4. Mobilization of CD34+ cells by glycosylated and nonglycosylated G-CSF in healthy volunteers--a comparative study.
Höglund M; Smedmyr B; Bengtsson M; Tötterman TH; Cour-Chabernaud V; Yver A; Simonsson B
Eur J Haematol; 1997 Sep; 59(3):177-83. PubMed ID: 9310126
[TBL] [Abstract][Full Text] [Related]
5. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
6. Lenograstim-mobilized peripheral blood progenitor cells in volunteer donors: an open label randomized split dose escalating study.
Basara N; Schmetzer B; Blau IW; Bischoff M; Günzelmann S; Kirsten D; Fauser AA
Bone Marrow Transplant; 2000 Feb; 25(4):371-6. PubMed ID: 10723579
[TBL] [Abstract][Full Text] [Related]
7. Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF.
Höglund M; Smedmyr B; Simonsson B; Tötterman T; Bengtsson M
Bone Marrow Transplant; 1996 Jul; 18(1):19-27. PubMed ID: 8831991
[TBL] [Abstract][Full Text] [Related]
8. Mobilization of peripheral blood stem cells by granulocyte-colony stimulating factors: comparison of a standard dose of glycosylated and mutated granulocyte-colony stimulating factor in non-Hodgkin's lymphoma patients following CHOP therapy.
Takemoto Y; Wada H; Takatsuka H; Okamoto T; Kakishita E
Drugs Exp Clin Res; 2000; 26(1):1-5. PubMed ID: 10761530
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of G-CSF and CD34+ cell mobilization after once or twice daily stimulation with rHu granulocyte-stimulating factor (lenograstim) in healthy volunteers: an intraindividual crossover study.
Kröger N; Sonnenberg S; Cortes-Dericks L; Freiberger P; Mollnau H; Zander AR
Transfusion; 2004 Jan; 44(1):104-10. PubMed ID: 14692975
[TBL] [Abstract][Full Text] [Related]
10. Lenograstim compared to filgrastim for the mobilization of hematopoietic stem cells in healthy donors.
Pérez-López O; Martín-Sánchez J; Parody-Porras R; Espigado-Tocino I; Noguerol P; Carmona-González M; Pérez-Simón JA
Transfusion; 2013 Dec; 53(12):3240-2. PubMed ID: 23489237
[TBL] [Abstract][Full Text] [Related]
11. Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors.
Farhan R; Urbanowska E; Zborowska H; Król M; Król M; Torosian T; Piotrowska I; Bogusz K; Skwierawska K; Wiktor-Jędrzejczak W; Snarski E
Ann Hematol; 2017 Oct; 96(10):1735-1739. PubMed ID: 28801752
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy and toxicity of lenograstim (glycosylated recombinant human granulocyte-colony stimulating factor) on peripheral blood stem cell harvest in healthy donors].
Kashiwagi H; Nishiura T; Ishikawa J; Yoshimura M; Kitayama H; Tomiyama Y; Matsuzawa Y
Gan To Kagaku Ryoho; 2001 Aug; 28(8):1105-9. PubMed ID: 11525026
[TBL] [Abstract][Full Text] [Related]
13. Collection of Ph-negative progenitor cells with granulocyte-colony stimulating factor in patients with chronic myeloid leukaemia who respond to recombinant alpha-interferon.
Reiffers J; Taylor K; Gluckman E; Gorin NC; Mahon FX; Micléa JM; Destrée D; Gautier L
Br J Haematol; 1998 Aug; 102(3):639-46. PubMed ID: 9722288
[TBL] [Abstract][Full Text] [Related]
14. Mobilization of hematopoietic progenitor stem cells in allogeneic setting with lenograstim by subcutaneous injection, in daily or twice-daily dosing: a single-center prospective study with historical control.
Martino M; Moscato T; Barillà S; Dattola A; Pontari A; Fedele R; Furlò G; Marzia Stilo C; Alberto Gallo G; Tripepi G
Transfusion; 2015 Aug; 55(8):2032-8. PubMed ID: 25857853
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human interleukin-3 (rhIL-3) enhances the mobilization of peripheral blood progenitor cells by recombinant human granulocyte colony-stimulating factor (rhG-CSF) in normal volunteers.
Huhn RD; Yurkow EJ; Tushinski R; Clarke L; Sturgill MG; Hoffman R; Sheay W; Cody R; Philipp C; Resta D; George M
Exp Hematol; 1996 Jun; 24(7):839-47. PubMed ID: 8647235
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34(+) peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors.
Sivgin S; Karakus E; Keklik M; Zararsiz G; Solmaz M; Kaynar L; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2016 Jun; 54(3):410-5. PubMed ID: 27052362
[TBL] [Abstract][Full Text] [Related]
17. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
[TBL] [Abstract][Full Text] [Related]
18. Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy.
Bojko P; Pawloski D; Stellberg W; Schröder JK; Seeber S
Ann Hematol; 2002 Sep; 81(9):522-8. PubMed ID: 12373354
[TBL] [Abstract][Full Text] [Related]
19. Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors.
Fischer JC; Frick M; Wassmuth R; Platz A; Punzel M; Wernet P
Br J Haematol; 2005 Sep; 130(5):740-6. PubMed ID: 16115131
[TBL] [Abstract][Full Text] [Related]
20. [Clinical study of single-dose G-CSF in mobilization and reconstruction of allogeneic peripheral blood stem cell transplantation].
Tian H; Zhou SY
Ai Zheng; 2003 Dec; 22(12):1325-9. PubMed ID: 14693061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
